HighTower Advisors LLC Invests $12.04 Million in Inhibrx, Inc. (NASDAQ:INBX)

HighTower Advisors LLC bought a new position in Inhibrx, Inc. (NASDAQ:INBXFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 781,752 shares of the company’s stock, valued at approximately $12,039,000. HighTower Advisors LLC owned approximately 5.40% of Inhibrx as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. bought a new position in shares of Inhibrx in the 4th quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Inhibrx in the 4th quarter worth approximately $47,000. New York State Common Retirement Fund purchased a new stake in shares of Inhibrx in the 4th quarter worth approximately $53,000. Exchange Traded Concepts LLC purchased a new stake in shares of Inhibrx in the 4th quarter worth approximately $148,000. Finally, Rhumbline Advisers purchased a new stake in shares of Inhibrx in the 4th quarter worth approximately $228,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Stock Performance

Inhibrx stock opened at $14.10 on Monday. The stock’s 50 day moving average is $13.38 and its 200 day moving average is $14.67. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $35.42.

Analysts Set New Price Targets

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Read Our Latest Research Report on INBX

About Inhibrx

(Free Report)

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

Featured Stories

Institutional Ownership by Quarter for Inhibrx (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.